有机化学    

研究论文

2,4-二酮内酰胺衍生物的设计合成及其抑制Mpro活性筛选

敖选丽a, 马超洁a, 王淑冰a, 何蕾a, 赏宇a, 朱锦阳a, 李建秀a, 张琴a, 张荣平a,*, 侯博a,*   

  1. a云南中医药大学中药学院暨云南省南药可持续利用研究重点实验室 云南 昆明 650500
  • 收稿日期:2026-03-15 修回日期:2026-04-09
  • 基金资助:
    国家自然科学基金项(82360690)、云南省基础研究计划 (202401AT070183)、中医药联合专项-面上项目 (202301AZ070001-044, 202401AZ070001-024)、云南省重点领域科技计划项目 (202303AC100025)、云南省科技厅重大科技专项计划 (202402AA310027)、云南省教育厅科学研究基金(No. 2025Y0598)资助项目.

Design, Synthesis and Mpro Inhibitory Activity Screening of 2,4-Diketolactam Derivatives

Xuan-Li Aoa, Chao-Jie Maa, Shu-Bing Wanga, Lei Hea, Jin-Yang Zhua, Jian-Xiu Lia, Qin Zhanga, Rong-Ping Zhanga,*, Bo Houa,*   

  1. aSchool of Chinese Materia Medica & Yunnan, Key Laboratory of Southern Medicine Utilization, Yunnan University of Chinese Medicine, Kunming 650500, China
  • Received:2026-03-15 Revised:2026-04-09
  • Contact: *Zhang Rong-Ping; Hou Bo. E-mail: zhrpkm@163. Com; kib_drug@163. com
  • Supported by:
    National Natural Science Foundation of China (NSFC) Project (82360690), Yunnan Province Basic Research Program (202401AT070183), Traditional Chinese Medicine (TCM) Joint Special Project - General Project (202301AZ070001-044, 202401AZ070001-024), Yunnan Province Key Fields Science and Technology Program (202303AC100025) and Major Science and Technology Special Project Program of Yunnan Provincial Department of Science and Technology (202402AA310027). Scientific Research Fund Project of the Department of Education of Yunnan Province (No. 2025Y0598)

β-丙氨酸乙酯盐酸盐和丙二酸单乙酯酰氯为原料合成2,4-二酮内酰胺衍生物, 获得25个2,4-二酮内酰胺衍生物t1-t25, 并评估其对Mpro的抑制活性. 化合物t5、t9、t18有较高的抑制率, 进一步对上述3个化合物梯度浓度抑制Mpro活性测试, 得到IC50分别为0.445 μM, 0.425 μM, 0.088 μM, 阳性对照奈玛特韦为0.426 μM, 抑制活性显示t5, t9的IC50与奈玛特韦相当, t18的IC50更低, 分子对接揭示t5作用于His41关键氨基酸, t9, t18与Mpro靶蛋白活性位点的关键氨基酸Cys145/His41共同作用. 本研究表明2,4-二酮内酰胺片段可成为抑制Mpro靶点的分子砌块, 上述三个化合物对冠状病毒Mpro具有较强抑制作用,可作为开发抗冠状病毒药物潜力化合物, 并为进一步药效学评价提供物质基础.

关键词: 冠状病毒, 2,4-二酮内酰胺衍生物, 主要蛋白酶, 抑制剂

In this study, twenty-five novel 2,4-diketolactam derivatives (t1-t25) were synthesized using β-alanine ethyl ester hydrochloride and monoethyl malonyl chloride as initial materials. The inhibitory activities of these compounds against the main protease (Mpro) were tested. The experimental results showed that t5, t9, and t18 exhibited relatively high Mpro inhibitory rates. Further gradient concentration assays of three compounds were conducted to evaluate the Mpro inhibitory activities. Their half-maximal inhibitory concentrations (IC50) against Mpro were 0.445 μM, 0.425 μM, and 0.088 μM, respectively, whereas the IC50 of nirmatrelvir was 0.426 μM. The inhibitory activity showed that the IC50 values of t5 and t9 were comparable to those of nirmatrelvir, while the IC50 value of t18 was lower. Molecular docking revealed that t5 bound to the key residue His41, while t9 and t18 interacted with both Cys145 and His41 in the active site of Mpro. This study demonstrates that the 2,4-diketolactam moiety can serve as a privileged building block for targeting the Mpro. The above three compounds exhibit potent inhibitory activity against coronavirus Mpro and represent promising candidates for the development of anti-coronavirus agents, providing a material basis for further pharmacodynamic evaluations.

Key words: Coronavirus, 2,4-Diketolactam Derivatives, Main protease, Inhibitors